Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance

Deal Details:
Sanofi has entered into a $110 million licensing deal with RadioMedix and Orano Med to develop AlphaMedix, a targeted radioligand therapy for neuroendocrine tumors.

Therapy Focus:
AlphaMedix uses lead-212Pb to deliver targeted radiation to cancer cells and has received Breakthrough Therapy Designation from the U.S. FDA for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Commercialization and Manufacturing:
Sanofi will oversee global commercialization, while Orano Med will handle manufacturing through a global platform under development.

Market Competition:
This deal sets up a rivalry with Novartis, which has two approved radioligand therapies, Pluvicto for prostate cancer and Lutathera for GEP-NETs.

Industry Trend:
Sanofi joins other Big Pharma companies like AstraZeneca, Bristol Myers Squibb, and Eli Lilly in entering the radioligand space, indicating a growing interest in this therapeutic area.